Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus cisplatin-based chemoradiotherapy versus placebo plus chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
NL-OMON45350Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Avelumab + standard chemoradiotherapy with Placebo + standard chemoradiotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Mar 2017; status: withdrawn.
02
Drugs
avelumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON45350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45350.